Trials / Completed
CompletedNCT02097082
Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System
An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- 480 Biomedical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.
Detailed description
The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | STANZA Drug-eluting resorbable Scaffold |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-03-30
- Completion
- 2017-05-01
- First posted
- 2014-03-26
- Last updated
- 2019-09-06
Locations
9 sites across 4 countries: Austria, Germany, New Zealand, Switzerland
Source: ClinicalTrials.gov record NCT02097082. Inclusion in this directory is not an endorsement.